Dear [ELECTED OFFICIAL],
As a constituent and an advocate with the Society for Immunotherapy of Cancer (SITC), I urge you to pass a final Fiscal Year 2026 Labor, Health and Human Services, and Education (LHHS) bill quickly and fund cancer research and prevention programs at the highest level possible.
Thanks to the National Institutes of Health (NIH), the National Cancer Institute (NCI), and the Centers for Disease Control and Prevention’s (CDC) cancer programs, the U.S. cancer death rate decreased by 30% between 1991 and 2021, with 4.1 million fewer cancer deaths. There are now over 18 million cancer survivors across the U.S.—the most ever. However, cancer is still the second leading cause of death in the nation, and there is so much more work to be done.
In addition to improving the lives of patients and their families, investments in NIH, NCI, CDC’s cancer programs, and the Advanced Research Projects Agency for Health (ARPA-H) strengthen the research workforce and drive economic growth by supporting more than 400,000 jobs and providing about $2.56 in new economic activity for every $1 invested in research funding. Additionally, ARPA-H drives innovation by focusing on high-risk, high-reward advancements in cancer technologies and approaches. These investments help the U.S. continue to lead on the global stage amid intensifying competition with other nations.
To maintain and continue the progress in cancer prevention and treatment, I urge you to support the highest possible funding levels in the FY26 LHHS bill, including at least $47.2 billion for NIH, $7.374 billion for NCI, $417.5 million for the CDC’s cancer prevention and control programs, and $1.5 billion for ARPA-H.
Patients and survivors are depending on you. Thank you for your support.
Sincerely,